Premature cardiovascular disease in chronic renal failure

Lancet

Volumn 356, Issue 9224, 2000, Pages 147-152

  Baigent, Colin ^a   Burbury, Kate ^a   Wheeler, David ^b  

^a RADCLIFFE INFIRMARY   (United Kingdom)

^b UNIVERSITY HOSPITALS BIRMINGHAM NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTIHYPERTENSIVE AGENT; ANTIOXIDANT; HYPOCHOLESTEROLEMIC AGENT; VITAMIN B GROUP;

CARDIOVASCULAR DISEASE; CHRONIC KIDNEY FAILURE; PRIORITY JOURNAL; REVIEW;

EID: 0034622282     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(00)02456-9     Document Type: Review

References (51)

1. Corti M-C., Guralnik J.M., Salive M.E.et al. Clarifying the direct relation between total cholesterol levels and death from coronary heart disease in older persons. Ann Intern Med. 126:1997;753-760.
2. US Renal Data System. 1999 Annual Data Report. Bethesda: National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, April 1999.
3. Foley R.N., Parfrey P.S., Sarnak M.J. Clinical epidemiology of cardiovascular disease in chronic renal disease. Am J Kidney Dis. 32(suppl 3):1998;S112-S119.
4. Jones C.A., McQuillan G.M., Kusek J.W.et al. Serum creatinine levels in the US population. Third National Health and Nutrition Examination Survey Am J Kidney Dis. 32:1998;992-999.
5. Wannamethee S.G., Shaper A.G., Perry I.J. Serum creatinine concentration and risk of cardiovascular disease. Stroke. 28:1997;557-563.
6. Foley R.N., Parfrey P.S., Harnett J.D.et al. Clinical and echocardiographic disease in patients starting end-stage renal disease therapy. Kidney Int. 47:1995;186-192.
7. London G.M., Marchais S.J., Guerin A.P., Metivier F., Pannier B. Cardiac hypertrophy and arterial alterations in end-stage renal disease; hemodynamic factors. Kidney Int. 43(suppl 41):1993;S42-S49.
8. Schwarz U., Buzello M., Ritz E.et al. Morphology of coronary atherosclerotic lesions in patients with end-stage renal failure. Nephrol Dial Transplant. 15:2000;218-223.
9. Rostand S.G., Kirk K.A., Rutsky E.A. Dialysis-associated ischaemic heart disease. insights from coronary angiography Kidney Int. 25:1984;653-659.
10. Perneger T.V., Klag M.J., Whelton P.K. Cause of death in patients with end-stage renal disease. death certificates vs registry reports Am J Public Health. 83:1993;1735-1738.
11. Clarke R., Shipley M., Lewington S.et al. Underestimation of risk associations due to regression dilution in long-term follow-up of prospective studies. Am J Epidemiol. 150:1999;341-353.
12. Edmunds M.E., Russell G.I. Hypertension in renal failure. Swales J.D. Textbook of hypertension. 1994;798-810 Blackwell Scientific Publications, Oxford.
13. Buckalew V.M. Jr., Berg R.L., Wang S.R., Porush J.G., Rauch S., Schulman G. Prevalence of hypertension in 1795 subjects with chronic renal disease: the Modification of Diet in Renal Disease Study baseline cohort. Am J Kidney Dis. 28:1996;811-821.
14. Levin A., Thompson C.R., Ethier J.et al. Left ventricular mass index increase in early renal disease. impact of decline in hemoglobin Am J Kidney Dis. 34:1999;125-134.
15. Zager P.G., Nikolic J., Brown R.H.et al. "U" curve association of blood pressure and mortality in dialysis patients. Kidney Int. 54:1998;561-569.
16. Foley R.N., Parfrey P.S., Harnett J.D., Kent G.M., Murray D.C., Barre P.E. Impact of hypertension on cardiomyopathy, morbidity and mortality in end-stage renal disease. Kidney Int. 49:1996;1379-1385.
17. MacMahon S. Blood pressure and the risks of cardiovascular disease. Swales J.D. Textbook of hypertension. 1994;46-57 Blackwell Scientific Publications, Oxford.
18. Levy D., Larson M.G., Vasan R.S., Kannel W., Ho K.K.L. The progression from hypertension to congestive heart failure. JAMA. 275:1996;1557-1562.
19. Cholesterol, diastolic blood pressure, and stroke: 13 000 strokes in 450 000 people in 45 prospective cohorts. Lancet. 346:1995;1647-1653.
20. Oda H., Keane W.F. Lipid abnormalities in end stage renal disease. Nephrol Dial Transplant. 13(Suppl 1):1998;45-49.
21. Fliser D., Pacini G., Engelleiter R.et al. Insulin resistance and hyperinsulinemia are already present in patients with incipient renal disease. Kidney Int. 53:1998;1343-1347.
22. Rajman I., Harper L., McPake D., Kendall M.J., Wheeler D.C. Low-density lipoprotein subfraction profiles in chronic renal failure. Nephrol Dial Transplant. 13:1998;2281-2287.
23. Grützmacher P., März W., Peschke B., Gross W., Schoeppe W. Lipoproteins and apolipoproteins during the progression of chronic renal disease. Nephron. 50:1988;103-111.
24. Lowrie E.G., Lew N.L. Death risk in hemodialysis patients. the predictive value of commonly measured variables and an evaluation of death rate differences between facilities Am J Kidney Dis. 15:1990;458-482.
25. Degoulet P., Legrain M., Réach I.et al. Mortality risk factors in patients treated by chronic hemodialysis: Report of the Diaphane Collaborative Study. Nephron. 31:1982;103-110.
26. Law M.R., Wald N.J., Wu T., Hackshaw A., Bailey A. Systematic underestimation of association between serum cholesterol concentration and ischaemic heart disease in observational studies. data from the BUPA study BMJ. 308:1994;363-366.
27. Baigent C., Armitage J. Cholesterol reduction among patients at increased risk of coronary heart disease. Proc R Coll Physicians Edinb. 29(Suppl 5):1999;10-15.
28. Bianchi S., Bigazzi R., Campese V.M. Microalbuminuria in essential hypertension. significance, pathophysiology, and therapeutic implications Am J Kidney Dis. 34:1999;973-995.
29. Warwick G.L., Packard C.J. Lipoprotein metabolism in the nephrotic syndrome. Nephrol Dial Transplant. 8:1993;385-396.
30. Law M.R., Wald N.J., Thompson S.G. By how much and how quickly does reduction in serum cholesterol concentration lower risk of ischaemic heart disease? BMJ. 308:1994;367-373.
31. Gordon D.J., Probstfield J.L., Garrison R.J.et al. High-density lipoprotein cholesterol and cardiovascular disease. four prospective American studies Circulation. 79:1989;8-15.
32. Sechi L.A., Zingaro L., De Carli S., Sechi G., Catena C., Falleti E. Increased serum lipoprotein (a) levels in patients with early renal failure. Ann Intern Med. 129:1998;457-461.
33. Kronenberg F., Utermann G., Dieplinger H. Lipoprotein[a] in renal disease. Am J Kidney Dis. 27:1996;1-25.
34. Kronenberg F., König P., Lhotta K.et al. Apolipoprotein[a] phenotype-associated decrease in lipoprotein[a] plasma concentrations after renal transplantation. Arterioscler Thromb. 14:1994;1399-1404.
35. Danesh J, Collins R, Peto R. Lipoprotein (a) and coronary heart disease: meta-analysis of prospective studies. Circulation 2000 (in press).
36. Jensen J.S., Borch-Johnsen K., Jensen G., Feldt-Rasmussen B. Microalbuminuria reflects a generalised transvascular albumin leakiness in clinically healthy subjects. Clin Sci. 88:1995;629-633.
37. Gilbert R.E., Cooper M.E., McNally P.G., O'Brien R.C., Taft J., Jerums G. Microalbuminuria; prognostic and therapeutic implications in diabetes mellitus. Diabet Med. 11:1994;636-645.
38. Dinneen S.F., Gerstein H.C. The association of microalbuminuria and mortality in non-insulin-dependent diabetes mellitus. a systematic overview of the literature Arch Intern Med. 157:1997;1413-1418.
39. Yudkin J.S., Forrest R.D., Jackson C.A. Microalbuminuria as predictor of vascular disease in non-diabetic subjects. Lancet. ii:1988;530-533.
40. Arnadottir M., Hultberg B., Nilsson-Ehle P., Thysell H. The effect of reduced glomerular filtration rate on plasma total homocysteine concentration. Scand J Clin Lab Invest. 56:1996;41-46.
41. Chauveau P., Chadefaux B., Coudé M.et al. Hyperhomocysteinaemia, a risk factor for atherosclerosis in chronic uremic patients. Kidney Int. 43(suppl 41):1993;S72-S77.
42. van Guldener C., Janssen M.J.F.M., Stehouwer C.D.A.et al. The effects of renal transplantation on hyperhomocysteinaemia in dialysis patients, and the estimation of renal homocysteine extraction in patients with normal renal function. Neth J Med. 52:1998;58-64.
43. Danesh J., Lewington S. Plasma homocysteine and coronary heart disease. systematic review of published epidemiological studies J Cardiovasc Risk. 5:1998;229-232.
44. Gabay C., Kushner I. Acute-phase proteins and other systemic responses to inflammation. N Engl J Med. 340:1999;448-454.
45. Danesh J., Collins R., Appleby P., Peto R. Association of fibrinogen, C-reactive protein, albumin, or leukocyte count with coronary heart disease. JAMA. 279:1998;1477-1482.
46. Irish A. Cardiovascular disease, fibrinogen and the acute phase response. associations with lipids and blood pressure in patients with chronic renal disease Atherosclerosis. 137:1998;133-139.
47. Scarabin P-Y., Bara L., Ricard S.et al. Genetic variation at the β-fibrinogen locus in relation to plasma fibrinogen concentrations and risk of myocardial infarction. the ECTIM study Arterioscler Thromb. 13:1993;886-891.
48. Foley R.N., Parfrey P.S., Harnett J.D., Kent G.M., Murray D.C., Barre P.E. The impact of anaemia on cardiomyopathy, morbidity and mortality in end-stage renal disease. Am J Kidney Dis. 28:1996;53-61.
49. Pascual J., Teruel J.L., Moya J.L., Liaño F., Jiménez-Mena M., Ortuño J. Regression of left ventricular hypertrophy after partial correction of anaemia with erythropoietin in patients on hemodialysis: a prospective study. Clin Nephrol. 35:1991;280-287.
50. Besarab A., Bolton W.K., Browne J.K.et al. The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoietin. N Engl J Med. 339:1998;584-590.
51. Baigent C, Wheeler D. Should we reduce blood cholesterol to prevent cardiovascular disease among patients with chronic renal failure? Nephrol Dial Transplant 2000 (in press).